Head to Head Survey: Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) & X4 Pharmaceuticals (NASDAQ:XFOR)

X4 Pharmaceuticals (NASDAQ:XFOR) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Earnings & Valuation

This table compares X4 Pharmaceuticals and Lakefront Biotherapeutics American Depositary Shares”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$15.85 million	19.46	-$79.20 million	($1.20)	-2.59
Lakefront Biotherapeutics American Depositary Shares	$1.26 billion	1.61	$363.05 million	($1.41)	-21.79

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than X4 Pharmaceuticals. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares X4 Pharmaceuticals and Lakefront Biotherapeutics American Depositary Shares’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings and recommmendations for X4 Pharmaceuticals and Lakefront Biotherapeutics American Depositary Shares, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1	1	4	0	2.50
Lakefront Biotherapeutics American Depositary Shares	0	5	3	1	2.56

X4 Pharmaceuticals presently has a consensus target price of $11.25, suggesting a potential upside of 261.74%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $37.00, suggesting a potential upside of 20.44%. Given X4 Pharmaceuticals’ higher probable upside, equities research analysts plainly believe X4 Pharmaceuticals is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Risk & Volatility

X4 Pharmaceuticals has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500.

Summary

Lakefront Biotherapeutics American Depositary Shares beats X4 Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.